Liposomal and/or nano-liposomal encapsulated HSP90a, HPf polypeptide (115 aa) and novel polypeptides HPf ΔC1 (101 aa) and HPfΔC2 (87 aa), as well as methods for manufacturing/preparing and using the compositions, are disclosed. Chimeric fusion proteins that include an HSP90a, HPf-polypeptide, HPf ΔC1 or HPfΔC2 polypeptide are presented. Transformed cell lines and expression vectors capable of expressing the chimeric fusion proteins, are provided. Methods for producing large amounts of recombinant HSP90a, HPf polypeptide, HPf ΔC1 or HPfΔC2 polypeptide, using expression vectors and transformed cell lines, are described. Topical and other delivery form preparations and methods for using the preparations, including methods for improving skin conditions (atopic dermatitis, wrinkles, skin elasticity, dark spots (over pigmentation), overall skin rejuvenation, skin ageing) for therapeutic and cosmeceutical uses are presented. Liposomal preparations and methods for using them for enhancing wound healing and methods for suppressing subcutaneous fat cell differentiation and reducing subcutaneous fat formation are disclosed.Linvention concerne HSP90a encapsulée, liposomale et/ou nano-liposomale, HPf polypeptide (115 aa) et de nouveaux polypeptides HPf ΔC1 (101 aa) et HPfΔC2 (87 aa), ainsi que des procédés de fabrication/préparation et dutilisation des compositions. Linvention concerne des protéines hybrides chimériques qui comprennent HSP90a, un polypeptide HPf, un polypeptide HPf ΔC1 ou HPfΔC2. Linvention concerne des lignées cellulaires transformées et des vecteurs dexpression qui sont apte à exprimer les protéines hybrides chimériques. Linvention concerne des procédés de production de grandes quantités de HSP90a, de polypeptide HPf, de polypeptide HPf ΔC1 ou HPfΔC2, à laide de vecteurs dexpression et de lignées cellulaires transformées. Linvention concerne des préparations de forme dadministration topique et dautres formes dadministration, et des procédés dutilisation des pr
